SG11201807077RA - Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof - Google Patents
Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereofInfo
- Publication number
- SG11201807077RA SG11201807077RA SG11201807077RA SG11201807077RA SG11201807077RA SG 11201807077R A SG11201807077R A SG 11201807077RA SG 11201807077R A SG11201807077R A SG 11201807077RA SG 11201807077R A SG11201807077R A SG 11201807077RA SG 11201807077R A SG11201807077R A SG 11201807077RA
- Authority
- SG
- Singapore
- Prior art keywords
- california
- gilead
- apollo
- llc
- foster city
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
- C12P41/001—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by metabolizing one of the enantiomers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Physics & Mathematics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Physics & Mathematics (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 8 September 2017 (08.09.2017) WIPO I PCT (10) International Publication Number WO 2017/151816 Al 1111111111111101110111111111110101111101110111111110111H01111111111111111110111111 (51) International Patent Classification: C07D 495/04 (2006.01) A61P 3/00 (2006.01) A61K 31/519 (2006.01) A61P 3/06 (2006.01) (21) International Application Number: PCT/US2017/020271 (22) International Filing Date: 1 March 2017 (01.03.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/302,755 2 March 2016 (02.03.2016) US 62/303,237 3 March 2016 (03.03.2016) US (71) Applicant: GILEAD APOLLO, LLC [US/US]; 333 Lakeside Drive, Foster City, California 94404 (US). (72) Inventors: ALEXANDER, Katy; c/o Gilead Apollo, LLC, 333 Lakeside Drive, Foster City, California 94404 (US). AMEDIO, John C., Jr.; c/o Gilead Apollo, LLC, 333 Lakeside Drive, Foster City, California 94404 (US). CALIMSIZ, Selcuk; c/o Gilead Apollo, LLC, 333 Lakeside Drive, Foster City, California 94404 (US). GEI- ER, Michael; c/o Gilead Apollo, LLC, 333 Lakeside Drive, Foster City, California 94404 (US). HARRIMAN, Geraldine C.; c/o Gilead Apollo, LLC, 333 Lakeside Drive, Foster City, California 94404 (US). HU, Sijun; c/o Gilead Apollo, LLC, 333 Lakeside Drive, Foster City, California 94404 (US). LAWSON, Jon P.; c/o Gilead Apollo, LLC, 333 Lakeside Drive, Foster City, California 94404 (US). MORRISON, Henry; c/o Gilead Apollo, LLC, 333 Lakeside Drive, Foster City, California 94404 (US). SABOURIN, Kyle; c/o Gilead Apollo, LLC, 333 Lakeside Drive, Foster City, California 94404 (US). SCOTT, Mark E.; c/o Gilead Apollo, LLC, 333 Lakeside Drive, Foster City, California 94404 (US). VARGHESE, Vimal; c/o Gilead Apollo, LLC, 333 Lakeside Drive, Foster City, California 94404 (US). VARIA, Kunal Arvind; c/o Gilead Apollo, LLC, 333 Lakeside Drive, Foster City, California 94404 (US). WANG, Xiaotin; c/o Gilead Apollo, LLC, 333 Lakeside Drive, Foster City, California 94404 (US). YANG, Xiaowei; c/o Gilead Apollo, LLC, 333 Lakeside Drive, Foster City, California 94404 (US). (74) Agents: TANNER, Lorna L. et al.; Sheppard Mullin Richter & Hampton LLP, 379 Lytton Avenue, Palo Alto, California 94301-1479 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Decl arations under Rule 4.17: as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Publ ished: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) W O 20 17 / 15 1816 Al (54) Title: SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF (57) : The present invention provides solid forms of compounds useful as inhibitors of Acetyl CoA Carboxylase (ACC), compositions thereof, methods of producing the same, and methods of using the same in the treatment of ACC-mediated diseases.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662302755P | 2016-03-02 | 2016-03-02 | |
| US201662303237P | 2016-03-03 | 2016-03-03 | |
| PCT/US2017/020271 WO2017151816A1 (en) | 2016-03-02 | 2017-03-01 | Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201807077RA true SG11201807077RA (en) | 2018-09-27 |
Family
ID=58347936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201807077RA SG11201807077RA (en) | 2016-03-02 | 2017-03-01 | Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US10183951B2 (en) |
| EP (2) | EP4364795A2 (en) |
| JP (3) | JP6944462B2 (en) |
| KR (2) | KR102622161B1 (en) |
| CN (2) | CN108699078A (en) |
| AU (3) | AU2017226267B2 (en) |
| BR (1) | BR112018067408A2 (en) |
| CA (4) | CA3172549A1 (en) |
| ES (1) | ES2972487T3 (en) |
| IL (1) | IL261255A (en) |
| MX (1) | MX2018010427A (en) |
| SG (1) | SG11201807077RA (en) |
| TW (2) | TWI788281B (en) |
| WO (1) | WO2017151816A1 (en) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI598347B (en) | 2009-07-13 | 2017-09-11 | 基利科學股份有限公司 | Apoptosis signal-regulating kinase inhibitors |
| AU2012335088B2 (en) | 2011-11-11 | 2017-08-24 | Gilead Apollo, Llc | ACC inhibitors and uses thereof |
| KR102443575B1 (en) | 2015-07-06 | 2022-09-16 | 길리애드 사이언시즈, 인코포레이티드 | Cot modulators and methods of use thereof |
| AR106472A1 (en) | 2015-10-26 | 2018-01-17 | Gilead Apollo Llc | ACC INHIBITORS AND USES OF THE SAME |
| JP2019502660A (en) | 2015-11-25 | 2019-01-31 | ギリアド アポロ， エルエルシー | Pyrazole ACC inhibitors and uses thereof |
| ES2855348T3 (en) | 2015-11-25 | 2021-09-23 | Gilead Apollo Llc | ACC ester inhibitors and uses thereof |
| JP2019503338A (en) | 2015-11-25 | 2019-02-07 | ギリアド アポロ， エルエルシー | Fungicidal composition comprising a derivative of 2,4-dioxo-1,4-dihydrothieno [2,3-d] pyrimidine |
| CA3172549A1 (en) | 2016-03-02 | 2017-09-08 | Gilead Apollo, Llc | Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof |
| AU2018227588B2 (en) * | 2017-03-03 | 2021-01-21 | Gilead Sciences, Inc. | Processes for preparing ACC inhibitors and solid forms thereof |
| KR20190126920A (en) | 2017-03-28 | 2019-11-12 | 길리애드 사이언시즈, 인코포레이티드 | Therapeutic Combinations for Treating Liver Disease |
| US10995099B2 (en) * | 2017-07-17 | 2021-05-04 | Nanjing Ruijie Pharmatech Co., Ltd. | Compounds and their uses as ACC inhibitors |
| KR20190036705A (en) * | 2017-09-28 | 2019-04-05 | 한미약품 주식회사 | Novel process for preparing (2r)-2-(2-methoxyphenyl)-2-(oxan-4-yloxy)ethan-1-ol compound and intermediates used therein |
| CA3077273A1 (en) | 2017-10-06 | 2019-04-11 | Gilead Sciences, Inc. | Combination therapy comprising an acc inhibitor |
| CN109810085B (en) * | 2019-04-19 | 2019-07-19 | 上海皓元生物医药科技有限公司 | The preparation method of ACC inhibitor and its intermediate |
| TWI770527B (en) | 2019-06-14 | 2022-07-11 | 美商基利科學股份有限公司 | Cot modulators and methods of use thereof |
| AR119594A1 (en) | 2019-08-09 | 2021-12-29 | Gilead Sciences Inc | THIENOPYRIMIDINE DERIVATIVES AS ACC INHIBITORS AND USES THEREOF |
| US20220347190A1 (en) | 2019-09-19 | 2022-11-03 | Novartis Ag | Treatment comprising fxr agonists |
| CN112574253B (en) * | 2019-09-29 | 2021-08-27 | 上海喀露蓝科技有限公司 | Phosphoric acid or phosphate ester derivative, preparation method and medical application thereof |
| CN110746439B (en) * | 2019-10-18 | 2020-10-30 | 南京瑞捷医药科技有限公司 | Preparation method of thienopyrimidinedione compound |
| CN112778325A (en) * | 2019-11-07 | 2021-05-11 | 南京瑞捷医药科技有限公司 | ACC inhibitor and application thereof |
| AU2020384883B2 (en) | 2019-11-15 | 2023-11-16 | Gilead Sciences, Inc. | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof |
| WO2021110135A1 (en) * | 2019-12-05 | 2021-06-10 | 漳州片仔癀药业股份有限公司 | Crystal form as inhibitor of acc1 and acc2, and preparation method therefor and use thereof |
| ES2960703T3 (en) | 2019-12-05 | 2024-03-06 | Zhangzhou Pien Tze Huang Pharm | Crystalline form of thieno[2,3-c]pyridazine-4(1H)-one compound, method of preparation thereof and use thereof |
| JP2023520650A (en) | 2020-03-30 | 2023-05-18 | ギリアード サイエンシーズ， インコーポレイテッド | (S)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1H-1,2,3-triazol-4-yl)2-methyl-1-oxo-1 ,2-dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carbonitrile Cot inhibitor compounds solid forms |
| KR20220160645A (en) | 2020-04-02 | 2022-12-06 | 길리애드 사이언시즈, 인코포레이티드 | Methods for preparing COT inhibitor compounds |
| US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
| JP2023529369A (en) | 2020-06-03 | 2023-07-10 | ギリアード サイエンシーズ， インコーポレイテッド | LPA receptor antagonists and their uses |
| CR20220609A (en) | 2020-06-03 | 2023-05-04 | Gilead Sciences Inc | Lpa receptor antagonists and uses thereof |
| EP4304711A1 (en) | 2021-03-11 | 2024-01-17 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| EP4313967A1 (en) | 2021-03-29 | 2024-02-07 | Gilead Sciences, Inc. | Khk inhibitors |
| US11980609B2 (en) | 2021-05-11 | 2024-05-14 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
| WO2022241023A1 (en) | 2021-05-13 | 2022-11-17 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| TW202304435A (en) | 2021-06-04 | 2023-02-01 | 美商基利科學股份有限公司 | Methods of treating nash |
| TW202311256A (en) | 2021-06-18 | 2023-03-16 | 美商基利科學股份有限公司 | Il-31 modulators for treating fxr-induced pruritis |
| KR102309616B1 (en) | 2021-07-27 | 2021-10-05 | 최금실 | Cosmetic composition comprising jojoba oil for skin regeneration and moisture, and preparing method the same |
| KR102337422B1 (en) | 2021-07-27 | 2021-12-08 | (주)최금실 | Cosmetic composition comprising jojoba oil for skin calming care and skin trouble improvement, and preparing method the same |
| US11939318B2 (en) | 2021-12-08 | 2024-03-26 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4670560A (en) | 1986-04-28 | 1987-06-02 | Ortho Pharmaceutical Corporation | Thienopyrimidine-2,4-dione derivatives and intermediates thereof |
| JPH02225485A (en) | 1989-02-27 | 1990-09-07 | Taiho Yakuhin Kogyo Kk | Thienopyrimidine-3-acetic acid derivative |
| WO1997007119A1 (en) | 1994-08-26 | 1997-02-27 | Takeda Chemical Industries, Ltd. | Thienopyrimidine derivatives, their production and use |
| JP3811196B2 (en) | 1993-08-26 | 2006-08-16 | 武田薬品工業株式会社 | Endothelin antagonist, thienopyrimidine derivative and process for producing the same |
| TW276256B (en) | 1993-08-26 | 1996-05-21 | Takeda Pharm Industry Co Ltd | |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| JPH09110873A (en) | 1995-08-17 | 1997-04-28 | Takeda Chem Ind Ltd | Thienopyrimidine derivative, its production and use |
| CA2250908C (en) | 1996-04-30 | 2012-03-13 | Takeda Chemical Industries, Ltd. | Combined use of gnrh agonist and antagonist |
| JP2007302703A (en) | 1996-04-30 | 2007-11-22 | Takeda Chem Ind Ltd | Medicinal composition |
| SE9702001D0 (en) | 1997-05-28 | 1997-05-28 | Astra Pharma Prod | Novel compounds |
| US6984644B2 (en) | 1997-05-28 | 2006-01-10 | Astrazeneca Ab | Treatment of skin disorders using thieno[2,3-D]pyrimidinediones |
| DE19754082A1 (en) | 1997-12-05 | 1999-06-10 | Knoll Ag | Method of combating obesity |
| CA2369981A1 (en) | 1999-04-09 | 2000-10-19 | Cell Therapeutics, Inc. | Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same |
| JP2004518732A (en) | 2001-02-14 | 2004-06-24 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | Thieno'2,3-D pyrimidinedione derivatives as matrix metalloproteinase inhibitors |
| US7655658B2 (en) | 2001-08-10 | 2010-02-02 | Palatin Technologies, Inc. | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds |
| ATE303178T1 (en) | 2002-02-27 | 2005-09-15 | Pfizer Prod Inc | ACC INHIBITORS |
| WO2004014916A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Pyrimidine fused bicyclic metalloproteinase inhibitors |
| EP1585392B1 (en) | 2003-01-06 | 2009-03-18 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Herbicides inhibiting the action of plant acetyl-coa carboxylase for use as pesticides. |
| ZA200506611B (en) | 2003-01-29 | 2006-12-27 | Takeda Pharmaceutical | Thienopyrimidine compounds and use thereof |
| WO2006014647A2 (en) | 2004-07-21 | 2006-02-09 | Athersys, Inc. | Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof |
| CA2644996A1 (en) | 2006-03-02 | 2007-09-13 | Cv Therapeutics, Inc. | A2a adenosine receptor antagonists |
| EP2151440A4 (en) | 2007-05-21 | 2010-10-20 | Takeda Pharmaceutical | Heterocyclic compound and use thereof |
| AU2009259839A1 (en) | 2008-06-20 | 2009-12-23 | Kinemed, Inc. | Compositions for the treatment of fibrotic diseases or conditions |
| WO2010050445A1 (en) | 2008-10-27 | 2010-05-06 | 武田薬品工業株式会社 | Bicyclic compound |
| US20100113473A1 (en) | 2008-10-30 | 2010-05-06 | Player Mark R | Aryl amide compound as an acetyl coenzyme a carboxylase inhibitor |
| MX2012007548A (en) | 2009-12-29 | 2012-07-23 | Poxel | Thieno [2,3-b] pyridinedione activators of ampk and therapeutic uses thereof. |
| WO2012090219A2 (en) | 2010-12-31 | 2012-07-05 | Jubilant Biosys Ltd. | Thiazole compounds useful as acetyl-coa carboxylase (acc) inhibitors |
| AU2012335088B2 (en) * | 2011-11-11 | 2017-08-24 | Gilead Apollo, Llc | ACC inhibitors and uses thereof |
| CN104541141B (en) | 2012-02-15 | 2017-08-18 | 罗伯特·博世有限公司 | Pressure sensor with doped electrode |
| JP5842804B2 (en) * | 2012-12-28 | 2016-01-13 | カシオ計算機株式会社 | Display terminal device and program |
| KR20160007598A (en) | 2013-05-10 | 2016-01-20 | 님버스 아폴로, 인코포레이티드 | Acc inhibitors and uses thereof |
| WO2014182950A1 (en) | 2013-05-10 | 2014-11-13 | Nimbus Apollo, Inc. | Acc inhibitors and uses thereof |
| WO2015007451A1 (en) * | 2013-07-15 | 2015-01-22 | Syngenta Participations Ag | Microbiocidal heterobicyclic derivatives |
| AU2016205138A1 (en) | 2015-01-09 | 2017-07-13 | Gilead Apollo, Llc | ACC inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease |
| AR106472A1 (en) * | 2015-10-26 | 2018-01-17 | Gilead Apollo Llc | ACC INHIBITORS AND USES OF THE SAME |
| SI3380479T1 (en) * | 2015-11-25 | 2023-04-28 | Gilead Apollo, Llc | Triazole acc inhibitors and uses thereof |
| JP2019503338A (en) | 2015-11-25 | 2019-02-07 | ギリアド アポロ， エルエルシー | Fungicidal composition comprising a derivative of 2,4-dioxo-1,4-dihydrothieno [2,3-d] pyrimidine |
| ES2855348T3 (en) | 2015-11-25 | 2021-09-23 | Gilead Apollo Llc | ACC ester inhibitors and uses thereof |
| JP2019502660A (en) * | 2015-11-25 | 2019-01-31 | ギリアド アポロ， エルエルシー | Pyrazole ACC inhibitors and uses thereof |
| CA3172549A1 (en) | 2016-03-02 | 2017-09-08 | Gilead Apollo, Llc | Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof |
| WO2018133858A1 (en) | 2017-01-22 | 2018-07-26 | Sunshine Lake Pharma Co., Ltd. | Thienopyrimidine derivative and use thereof in medicine |
| KR20190036705A (en) | 2017-09-28 | 2019-04-05 | 한미약품 주식회사 | Novel process for preparing (2r)-2-(2-methoxyphenyl)-2-(oxan-4-yloxy)ethan-1-ol compound and intermediates used therein |
-
2017
- 2017-03-01 CA CA3172549A patent/CA3172549A1/en active Pending
- 2017-03-01 CN CN201780014543.0A patent/CN108699078A/en active Pending
- 2017-03-01 CA CA3155220A patent/CA3155220C/en active Active
- 2017-03-01 EP EP23219327.6A patent/EP4364795A2/en active Pending
- 2017-03-01 MX MX2018010427A patent/MX2018010427A/en unknown
- 2017-03-01 JP JP2018545600A patent/JP6944462B2/en active Active
- 2017-03-01 CA CA3015526A patent/CA3015526C/en active Active
- 2017-03-01 CN CN202110182955.3A patent/CN112920200A/en active Pending
- 2017-03-01 KR KR1020187027295A patent/KR102622161B1/en active IP Right Grant
- 2017-03-01 KR KR1020237007117A patent/KR20230035692A/en not_active Application Discontinuation
- 2017-03-01 ES ES17711446T patent/ES2972487T3/en active Active
- 2017-03-01 AU AU2017226267A patent/AU2017226267B2/en active Active
- 2017-03-01 TW TW106106735A patent/TWI788281B/en active
- 2017-03-01 US US15/446,873 patent/US10183951B2/en active Active
- 2017-03-01 WO PCT/US2017/020271 patent/WO2017151816A1/en active Application Filing
- 2017-03-01 TW TW111147581A patent/TWI818828B/en active
- 2017-03-01 CA CA3220447A patent/CA3220447A1/en active Pending
- 2017-03-01 EP EP17711446.9A patent/EP3423456B1/en active Active
- 2017-03-01 SG SG11201807077RA patent/SG11201807077RA/en unknown
- 2017-03-01 BR BR112018067408A patent/BR112018067408A2/en not_active Application Discontinuation
-
2018
- 2018-08-20 IL IL261255A patent/IL261255A/en unknown
- 2018-12-12 US US16/217,935 patent/US10487090B2/en active Active
-
2019
- 2019-10-10 US US16/598,411 patent/US11104687B2/en active Active
-
2021
- 2021-07-26 AU AU2021209149A patent/AU2021209149B2/en active Active
- 2021-08-03 US US17/393,030 patent/US11912718B2/en active Active
- 2021-09-10 JP JP2021147802A patent/JP7184988B2/en active Active
-
2022
- 2022-11-24 JP JP2022187472A patent/JP7356564B2/en active Active
-
2023
- 2023-07-18 AU AU2023206094A patent/AU2023206094A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201807077RA (en) | Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof | |
| SG11201908532UA (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201807269PA (en) | Filamentous fungal biomats, methods of their production and methods of their use | |
| SG11201811491YA (en) | Quinazoline and indole compounds to treat medical disorders | |
| SG11201806302RA (en) | Inhibitors of receptor-interacting protein kinase 1 | |
| SG11201907056XA (en) | Compositions and methods for the treatment of hemoglobinopathies | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201809714TA (en) | Piperidines as menin inhibitors | |
| SG11201804294WA (en) | Tank-binding kinase inhibitor compounds | |
| SG11201900135YA (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201408739VA (en) | Inhibitors of hepatitis c virus | |
| SG11201407115XA (en) | Carboxylic acid compounds | |
| SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
| SG11201408013WA (en) | Solid forms of an antiviral compound | |
| SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
| SG11201906163TA (en) | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus | |
| SG11201804890TA (en) | Bipyrazolyl derivatives useful for the treatment of autoimmune diseases | |
| SG11201805595TA (en) | Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid | |
| SG11201900464TA (en) | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201811686UA (en) | 18f-labeled triazole containing psma inhibitors | |
| SG11201909376TA (en) | Crystalline forms of a jak inhibitor compound |